相似文献
1
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.
Gut. 2006 Mar;55 Suppl 1(Suppl 1):i36-58. doi: 10.1136/gut.2005.081950c.
2
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.
J Crohns Colitis. 2010 Feb;4(1):63-101. doi: 10.1016/j.crohns.2009.09.009. Epub 2009 Dec 21.
3
European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
Gut. 2006 Mar;55 Suppl 1(Suppl 1):i16-35. doi: 10.1136/gut.2005.081950b.
4
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101.
5
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.
6
Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Dan Med Bull. 2011 Dec;58(12):B4360.
7
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
8
Prevention of postoperative recurrence in Crohn's disease.
Clin Gastroenterol Hepatol. 2008 Jun;6(6):616-20. doi: 10.1016/j.cgh.2007.08.020. Epub 2007 Oct 29.
9
Management of inflammatory bowel disease.
Am Fam Physician. 1998 Jan 1;57(1):57-68, 71-2.
10
[Postoperative recurrence in Crohn's disease].
Chir Ital. 1995;47(5):25-32.
引用本文的文献
1
Current practice and innovations in diagnosing perianal fistulizing Crohn's disease (pfCD): a narrative review.
Tech Coloproctol. 2025 Apr 15;29(1):102. doi: 10.1007/s10151-025-03122-6.
2
Vaginal delivery in women with perianal Crohn's disease: why not?
AJOG Glob Rep. 2024 Mar 14;4(2):100333. doi: 10.1016/j.xagr.2024.100333. eCollection 2024 May.
3
Optimising surgical anastomosis in ileocolic resection for Crohn's disease with respect to recurrence and functionality: two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES).
BMC Surg. 2024 Feb 26;24(1):71. doi: 10.1186/s12893-024-02340-3.
4
The mode of delivery does not influence the occurrence of post-partum perianal disease flares in patients with inflammatory bowel disease.
BMC Gastroenterol. 2024 Jan 16;24(1):34. doi: 10.1186/s12876-023-03018-5.
5
Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.
World J Gastroenterol. 2023 Nov 14;29(42):5728-5750. doi: 10.3748/wjg.v29.i42.5728.
6
New pattern of individualized management of chronic diseases: focusing on inflammatory bowel diseases and looking to the future.
Front Med (Lausanne). 2023 May 10;10:1186143. doi: 10.3389/fmed.2023.1186143. eCollection 2023.
7
Erythema Nodosum following Infection: A Case Report.
Medicina (Kaunas). 2022 Dec 19;58(12):1873. doi: 10.3390/medicina58121873.
8
It is not NOD2 - genetic and clinical risk factors for postoperative complications following ileocolic resection in Crohn's disease.
Int J Colorectal Dis. 2022 Aug;37(8):1901-1908. doi: 10.1007/s00384-022-04223-6. Epub 2022 Aug 1.
9
A Novel Clinical Radiomics Nomogram to Identify Crohn's Disease from Intestinal Tuberculosis.
J Inflamm Res. 2021 Dec 3;14:6511-6521. doi: 10.2147/JIR.S344563. eCollection 2021.
10
Review of pregnancy in Crohn's disease and ulcerative colitis.
Therap Adv Gastroenterol. 2021 May 18;14:17562848211016242. doi: 10.1177/17562848211016242. eCollection 2021.
本文引用的文献
1
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
Gut. 2006 Apr;55(4):505-9. doi: 10.1136/gut.2005.074815. Epub 2005 Sep 27.
2
Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.
J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):1-7. doi: 10.1097/01.mpg.0000163736.30261.82.
3
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Health Technol Assess. 2005 Jun;9(22):1-160. doi: 10.3310/hta9220.
4
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
Gastroenterology. 2005 Apr;128(4):862-9. doi: 10.1053/j.gastro.2005.01.048.
5
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.
Gastroenterology. 2005 Apr;128(4):856-61. doi: 10.1053/j.gastro.2005.01.010.
6
Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey.
Inflamm Bowel Dis. 2005 Mar;11(3):287-95. doi: 10.1097/01.mib.0000160771.71328.6c.
7
Pharmacotherapy of osteoporosis in men.
Expert Opin Pharmacother. 2005 Jan;6(1):45-58. doi: 10.1517/14656566.6.1.45.
8
Sclerosing cholangitis.
Curr Opin Gastroenterol. 2004 May;20(3):275-80. doi: 10.1097/00001574-200405000-00013.
9
MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study.
Scand J Rheumatol. 2004;33(5):332-8. doi: 10.1080/03009740410005881.
10
Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Anticancer Res. 2004 Sep-Oct;24(5B):3121-7.
Zotero 插件